Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.

Sinicrope FA, Velamala PR, Wong Kee Song LM, Viggiano TR, Bruining DH, Rajan E, Gostout C, Kriachley RE, Buttar NS, Schroeder KW, Kisiel JB, Larson MV, Sweetser SR, Sedlack RR, Sinicrope SN, Richmond E, Umar A, Della'Zanna G, Noaeill JS, Meyers J, Foster NR.

Cancer Prev Res (Phila). 2019 Sep 4. pii: canprevres.0167.2019. doi: 10.1158/1940-6207.CAPR-19-0167. [Epub ahead of print]

PMID:
31484660
2.

Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma.

Ma DJ, Price KA, Moore EJ, Patel SH, Hinni ML, Garcia JJ, Graner DE, Foster NR, Ginos B, Neben-Wittich M, Garces YI, Chintakuntlawar AV, Price DL, Olsen KD, Van Abel KM, Kasperbauer JL, Janus JR, Waddle M, Miller R, Shiraishi S, Foote RL.

J Clin Oncol. 2019 Aug 1;37(22):1909-1918. doi: 10.1200/JCO.19.00463. Epub 2019 Jun 4.

PMID:
31163012
3.

A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).

Halfdanarson TR, Foster NR, Kim GP, Meyers JP, Smyrk TC, McCullough AE, Ames MM, Jaffe JP, Alberts SR.

Oncologist. 2019 May;24(5):589-e160. doi: 10.1634/theoncologist.2018-0878. Epub 2019 Jan 24.

4.

Subgram-Scale Synthesis of Biomass Waste-Derived Fluorescent Carbon Dots in Subcritical Water for Bioimaging, Sensing, and Solid-State Patterning.

Su R, Wang D, Liu M, Yan J, Wang JX, Zhan Q, Pu Y, Foster NR, Chen JF.

ACS Omega. 2018 Oct 31;3(10):13211-13218. doi: 10.1021/acsomega.8b01919. Epub 2018 Oct 15.

5.

Kinase Targets for Mycolic Acid Biosynthesis in Mycobacterium tuberculosis.

Alsayed SSR, Beh CC, Foster NR, Payne AD, Yu Y, Gunosewoyo H.

Curr Mol Pharmacol. 2019;12(1):27-49. doi: 10.2174/1874467211666181025141114. Review.

PMID:
30360731
6.

The duality of ocean acidification as a resource and a stressor.

Connell SD, Doubleday ZA, Foster NR, Hamlyn SB, Harley CDG, Helmuth B, Kelaher BP, Nagelkerken I, Rodgers KL, SarĂ  G, Russell BD.

Ecology. 2018 May;99(5):1005-1010. doi: 10.1002/ecy.2209.

PMID:
29714829
7.

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC.

J Clin Oncol. 2018 May 10;36(14):1412-1418. doi: 10.1200/JCO.2017.77.0388. Epub 2018 Mar 27. Erratum in: J Clin Oncol. 2018 Aug 1;36(22):2360.

8.

North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.

McWilliams RR, Foster NR, Mahoney MR, Smyrk TC, Murray JA, Ames MM, Horvath LE, Schneider DJ, Hobday TJ, Jatoi A, Meyers JP, Goetz MP.

Cancer. 2017 Sep 15;123(18):3494-3501. doi: 10.1002/cncr.30766. Epub 2017 May 10.

9.

Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.

Colon-Otero G, Weroha SJ, Foster NR, Haluska P, Hou X, Wahner-Hendrickson AE, Jatoi A, Block MS, Dinh TA, Robertson MW, Copland JA.

Gynecol Oncol. 2017 Jul;146(1):64-68. doi: 10.1016/j.ygyno.2017.04.020. Epub 2017 Apr 28.

PMID:
28461031
10.

Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.

Weinberg DS, Lin JE, Foster NR, Della'Zanna G, Umar A, Seisler D, Kraft WK, Kastenberg DM, Katz LC, Limburg PJ, Waldman SA.

Cancer Prev Res (Phila). 2017 Jun;10(6):345-354. doi: 10.1158/1940-6207.CAPR-16-0286. Epub 2017 Apr 10.

11.

Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance).

Jansson-Knodell CL, Foster NR, Sargent DJ, Limburg PJ, Thibodeau SN, Smyrk TC, Sinicrope FA, Jahagirdar B, Goldberg RM, Alberts SR.

J Gastrointest Oncol. 2017 Feb;8(1):1-11. doi: 10.21037/jgo.2016.12.13.

12.

Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.

Wang X, Wang X, Hodgson L, George SL, Sargent DJ, Foster NR, Ganti AK, Stinchcombe TE, Crawford J, Kratzke R, Adjei AA, Kindler HL, Vokes EE, Pang H.

Oncologist. 2017 Feb;22(2):189-198. doi: 10.1634/theoncologist.2016-0121. Epub 2017 Feb 10.

13.

Improving the dissolution properties of curcumin using dense gas antisolvent technology.

Kurniawansyah F, Quachie L, Mammucari R, Foster NR.

Int J Pharm. 2017 Apr 15;521(1-2):239-248. doi: 10.1016/j.ijpharm.2017.02.018. Epub 2017 Feb 6.

PMID:
28185959
14.

How ocean acidification can benefit calcifiers.

Connell SD, Doubleday ZA, Hamlyn SB, Foster NR, Harley CDG, Helmuth B, Kelaher BP, Nagelkerken I, SarĂ  G, Russell BD.

Curr Biol. 2017 Feb 6;27(3):R95-R96. doi: 10.1016/j.cub.2016.12.004.

15.

Survival analyses in lung cancer.

Chansky K, Subotic D, Foster NR, Blum T.

J Thorac Dis. 2016 Nov;8(11):3457-3463. doi: 10.21037/jtd.2016.11.28.

16.

Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).

Singh PP, Shi Q, Foster NR, Grothey A, Nair SG, Chan E, Shields AF, Goldberg RM, Gill S, Kahlenberg MS, Sinicrope FA, Sargent DJ, Alberts SR.

Oncologist. 2016 Dec;21(12):1509-1521. Epub 2016 Nov 23.

17.

A Single-Institution Study of Demographics and Outcomes of Adult Patients With Multiple Cancers.

Ho TP, Foster NR, Jatoi A.

Cancer Control. 2016 Oct;23(4):455-460.

PMID:
27842336
18.

Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma.

Yoon HH, Lewis MA, Foster NR, Sukov WR, Khan M, Sattler CA, Wiktor AE, Wu TT, Jenkins RB, Sinicrope FA.

Int J Cancer. 2016 Oct 1;139(7):1626-31. doi: 10.1002/ijc.30200. Epub 2016 Jun 10.

19.

A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032).

Kent MS, Mandrekar SJ, Landreneau R, Nichols F, Foster NR, DiPetrillo TA, Meyers B, Heron DE, Jones DR, Tan AD, Starnes S, Putnam JB Jr, Fernando HC.

Ann Thorac Surg. 2016 Jul;102(1):239-46. doi: 10.1016/j.athoracsur.2016.01.063. Epub 2016 Apr 19.

20.

Should Vital Signs Be Routinely Obtained Prior to Intravenous Chemotherapy? Results From a 2-Center Study.

Menon S, Foster NR, Looker S, Sorgatz K, Kasi PM, McWilliams RR, Jatoi A.

Cancer Control. 2015 Oct;22(4):515-9.

PMID:
26678980
21.

Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).

Yoon HH, Foster NR, Meyers JP, Steen PD, Visscher DW, Pillai R, Prow DM, Reynolds CM, Marchello BT, Mowat RB, Mattar BI, Erlichman C, Goetz MP.

Ann Oncol. 2016 Feb;27(2):339-44. doi: 10.1093/annonc/mdv543. Epub 2015 Nov 16.

22.

Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival.

Jatoi A, Foster NR, Kalli KR, Vierkant RA, Zhang Z, Larson MC, Fridley B, Goode EL.

BMC Cancer. 2015 Oct 15;15:711. doi: 10.1186/s12885-015-1774-z.

23.

Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.

Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ.

J Thorac Oncol. 2015 Jul;10(7):1099-106. doi: 10.1097/JTO.0000000000000548.

24.

Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).

Ma BB, Goh BC, Lim WT, Hui EP, Tan EH, Lopes Gde L, Lo KW, Li L, Loong H, Foster NR, Erlichman C, King AD, Kam MK, Leung SF, Chan KC, Chan AT.

Invest New Drugs. 2015 Aug;33(4):985-91. doi: 10.1007/s10637-015-0264-0. Epub 2015 Jun 19.

PMID:
26084990
25.

Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.

Pedersen KS, Kim GP, Foster NR, Wang-Gillam A, Erlichman C, McWilliams RR.

Invest New Drugs. 2015 Aug;33(4):963-8. doi: 10.1007/s10637-015-0246-2. Epub 2015 May 8.

26.

Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma.

Zaanan A, Park JM, Tougeron D, Huang S, Wu TT, Foster NR, Sinicrope FA.

Int J Cancer. 2015 Sep 15;137(6):1498-502. doi: 10.1002/ijc.29496. Epub 2015 Mar 9.

27.

A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients.

Jatoi A, Radecki Breitkopf C, Foster NR, Block MS, Grudem M, Wahner Hendrickson A, Carlson RE, Barrette B, Karlin N, Fields AP.

Oncology. 2015;88(4):208-13. doi: 10.1159/000369257. Epub 2014 Dec 6.

28.

Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis.

Rule WG, Foster NR, Meyers JP, Ashman JB, Vora SA, Kozelsky TF, Garces YI, Urbanic JJ, Salama JK, Schild SE.

J Geriatr Oncol. 2015 Mar;6(2):119-26. doi: 10.1016/j.jgo.2014.11.002. Epub 2014 Dec 4.

29.

Hydronephrosis in patients with cervical cancer: an assessment of morbidity and survival.

Patel K, Foster NR, Kumar A, Grudem M, Longenbach S, Bakkum-Gamez J, Haddock M, Dowdy S, Jatoi A.

Support Care Cancer. 2015 May;23(5):1303-9. doi: 10.1007/s00520-014-2482-y. Epub 2014 Oct 23.

30.

MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial.

Pavelitz T, Renfro L, Foster NR, Caracol A, Welsch P, Lao VV, Grady WB, Niedzwiecki D, Saltz LB, Bertagnolli MM, Goldberg RM, Rabinovitch PS, Emond M, Monnat RJ Jr, Maizels N.

PLoS One. 2014 Oct 13;9(10):e108483. doi: 10.1371/journal.pone.0108483. eCollection 2014.

31.

A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.

Zhao Y, Foster NR, Meyers JP, Thomas SP, Northfelt DW, Rowland KM Jr, Mattar BI, Johnson DB, Molina JR, Mandrekar SJ, Schild SE, Bearden JD 3rd, Aubry MC, Adjei AA.

J Thorac Oncol. 2015 Jan;10(1):172-80. doi: 10.1097/JTO.0000000000000383.

32.

Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus.

Chak A, Buttar NS, Foster NR, Seisler DK, Marcon NE, Schoen R, Cruz-Correa MR, Falk GW, Sharma P, Hur C, Katzka DA, Rodriguez LM, Richmond E, Sharma AN, Smyrk TC, Mandrekar SJ, Limburg PJ; Cancer Prevention Network.

Clin Gastroenterol Hepatol. 2015 Apr;13(4):665-72.e1-4. doi: 10.1016/j.cgh.2014.08.040. Epub 2014 Sep 15.

33.

Influence of patient's physiologic factors and immobilization choice with stereotactic body radiotherapy for upper lung tumors.

Sio TT, Jensen AR, Miller RC, Fong de los Santos LE, Hallemeier CL, Foster NR, Park SS, Bauer HJ, Chang K, Garces YI, Olivier KR.

J Appl Clin Med Phys. 2014 Sep 8;15(5):4931. doi: 10.1120/jacmp.v15i5.4931.

34.

Formation of nanocarrier systems by dense gas processing.

Beh CC, Mammucari R, Foster NR.

Langmuir. 2014 Sep 23;30(37):11046-54. doi: 10.1021/la502594k. Epub 2014 Sep 15.

PMID:
25162492
35.

A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.

Molina JR, Foster NR, Reungwetwattana T, Nelson GD, Grainger AV, Steen PD, Stella PJ, Marks R, Wright J, Adjei AA.

Lung Cancer. 2014 Aug;85(2):245-50. doi: 10.1016/j.lungcan.2014.03.004. Epub 2014 May 1.

36.

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.

Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ Jr, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM; Alliance for Clinical Trials in Oncology.

Gastroenterology. 2014 Sep;147(3):637-45. doi: 10.1053/j.gastro.2014.05.009. Epub 2014 May 21.

37.

Patients' rationale for declining participation in a cancer-associated weight loss study.

Wanger T, Foster NR, Nguyen PL, Jatoi A.

J Cachexia Sarcopenia Muscle. 2014 Jun;5(2):121-5. doi: 10.1007/s13539-014-0128-z. Epub 2014 Mar 13.

38.

Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab.

Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH.

Pancreas. 2014 Apr;43(3):343-9. doi: 10.1097/MPA.0000000000000095.

39.

Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature.

Patel K, Foster NR, Farrell A, Le-Lindqwister NA, Mathew J, Costello B, Reynolds J, Meyers JP, Jatoi A.

J Cancer Educ. 2013 Dec;28(4):770-6. doi: 10.1007/s13187-013-0511-z. Review.

40.

Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.

Arcaroli J, Quackenbush K, Dasari A, Powell R, McManus M, Tan AC, Foster NR, Picus J, Wright J, Nallapareddy S, Erlichman C, Hidalgo M, Messersmith WA.

Cancer Med. 2012 Oct;1(2):207-17. doi: 10.1002/cam4.27. Epub 2012 Aug 16.

41.

Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.

Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, Goldberg RM, Degramont A, O'Connell MJ, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group.

Cancer. 2013 Apr 15;119(8):1528-36. doi: 10.1002/cncr.27938. Epub 2013 Jan 10.

42.

Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy.

Park JM, Huang S, Wu TT, Foster NR, Sinicrope FA.

Cancer Biol Ther. 2013 Feb;14(2):100-7. doi: 10.4161/cbt.22954. Epub 2012 Nov 28.

43.

Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas.

Yoon HH, Orrock JM, Foster NR, Sargent DJ, Smyrk TC, Sinicrope FA.

PLoS One. 2012;7(8):e42274. doi: 10.1371/journal.pone.0042274. Epub 2012 Aug 6.

44.

Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial.

Holtan SG, Steen PD, Foster NR, Erlichman C, Medeiros F, Ames MM, Safgren SL, Graham DL, Behrens RJ, Goetz MP.

PLoS One. 2012;7(7):e39285. doi: 10.1371/journal.pone.0039285. Epub 2012 Jul 17.

45.

A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.

Falk GW, Buttar NS, Foster NR, Ziegler KL, Demars CJ, Romero Y, Marcon NE, Schnell T, Corley DA, Sharma P, Cruz-Correa MR, Hur C, Fleischer DE, Chak A, Devault KR, Weinberg DS, Della'Zanna G, Richmond E, Smyrk TC, Mandrekar SJ, Limburg PJ; Cancer Prevention Network.

Gastroenterology. 2012 Oct;143(4):917-26.e1. doi: 10.1053/j.gastro.2012.06.044. Epub 2012 Jul 11.

46.

Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis.

Schild SE, Foster NR, Meyers JP, Ross HJ, Stella PJ, Garces YI, Olivier KR, Molina JR, Past LR, Adjei AA; North Central Cancer Treatment Group.

Ann Oncol. 2012 Nov;23(11):2919-24. doi: 10.1093/annonc/mds123. Epub 2012 Jul 10.

47.

Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials.

Sinicrope FA, Foster NR, Yoon HH, Smyrk TC, Kim GP, Allegra CJ, Yothers G, Nikcevich DA, Sargent DJ.

J Clin Oncol. 2012 Feb 1;30(4):406-12. doi: 10.1200/JCO.2011.39.2563. Epub 2011 Dec 27.

48.

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ.

J Natl Cancer Inst. 2011 Jun 8;103(11):863-75. doi: 10.1093/jnci/djr153. Epub 2011 May 19. Erratum in: J Natl Cancer Inst. 2011 Nov 2;103(21):1639. Kim, George P [added].

49.

Application of a dense gas technique for sterilizing soft biomaterials.

Karajanagi SS, Yoganathan R, Mammucari R, Park H, Cox J, Zeitels SM, Langer R, Foster NR.

Biotechnol Bioeng. 2011 Jul;108(7):1716-25. doi: 10.1002/bit.23105. Epub 2011 Mar 21.

50.

Particle formation of budesonide from alcohol-modified subcritical water solutions.

Carr AG, Mammucari R, Foster NR.

Int J Pharm. 2011 Feb 28;405(1-2):169-80. doi: 10.1016/j.ijpharm.2010.11.042. Epub 2010 Dec 1.

PMID:
21129462

Supplemental Content

Loading ...
Support Center